A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
Latest Information Update: 03 Nov 2023
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 28 Jun 2022 Results reporting long term relapse-risk-reduction efficacy and safety data from two clinical studies: PREVENT (NCT01892345) and its OLE (NCT02003144) presented at the 8th Congress of the European Academy of Neurology
- 06 Apr 2022 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Results from PREVENT and its open-label extension study (NCT01892345, NCT02003144) published in the Multiple Sclerosis Journal